NeurologyLive® Friday 5 — December 17, 2021

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: The Expansion Toward Integrative Wellness Approaches in MS Care

As part of NeurologyLive^®'s participation in our sister publication HCPLive^®'s "This Year in Medicine" series, our team dove deep into the use of integrative wellness approaches in multiple sclerosis as clinicians have begun to utilize this approach in the treatment of symptoms by focusing on better overall health, exercising, and dieting. Featuring insight from from Kathy Zackowski, PhD, OTR; Mona Bostick, RDN, LDN; and Mitzi Joi Williams, MD.

2: Peers & Perspectives: Collaboration and Communication While Treating Patients With Dravet and LGS

Elizabeth Thiele, MD, PhD, and Elaine C. Wirrell, MD, explain how community neurologists can work with academic center to treat patients with Dravet or Lennox-Gastaut syndromes in episode 9 of the NeurologyLive® Peers & Perspectives series, "Rare Childhood Epilepsies: Dravet Syndrome and Lennox-Gastaut Syndrome."

3: NeuroVoices: Darcy Krueger, MD, PhD, on Ganaxolone, Genetics, and Drug Development for Tuberous Sclerosis

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s provided insight on promising drug developments for tuberous sclerosis complex and other notable priorities within the space. He claims that although drug development for this space is among the top priorities, there are several other aspects that need continued research, including expanding more on the role of genetics.

4: Podcast Episode 53: A Landmark Year for Alzheimer Disease

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Anton Porsteinsson, MD, who shared his perspective on the progress made in Alzheimer disease in 2021, from the first approval since 2003 to the agents moving through the pipeline and the improved understanding of AD pathology, and offered a look into what the future may hold.

5: Peer Exchange: Pyrimidine Synthesis Inhibitors for RRMS

In episode 8 of the NeurologyLive® Peer Exchange series, "Oral Therapy Options for Relapsing-Remitting Multiple Sclerosis," Gabrielle Macaron, MD; Jennifer Graves, MD, PhD, MAS; and Suma Shah, MD, discuss the advantages of using the pyrimidine synthesis inhibitor teriflunomide to treat relapsing-remitting multiple sclerosis.

—————————————————

Introducing: Giants of Multiple Sclerosis™

Recognize and celebrate the individuals who have achieved landmark successes within multiple sclerosis! Giants of Multiple Sclerosis™ is a premier neuroscience award that celebrates pioneers, innovators, and future generations of leaders who have been selected by their peers for their remarkable achievements in Multiple Sclerosis.

Nominate Someone Today for a 2022 Giants of Multiple Sclerosis™ Award

• Nominations are open through January 31, 2022
• The Giants of Multiple Sclerosis™ Steering Committee will vet all nominations and vote to determine the 2022 inductees
• Nominees will be selected on the merits of their lifetime work.
• One honoree in each category who makes a measurable difference in the lives of patients will be awarded.
• The 2022 Giants of Multiple Sclerosis™ inaugural class will be announced in Spring of 2022

Nominate someone here.